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OBJECTIVES We sought to determine whether abciximab therapy at the time of percutaneous coronary
intervention (PCI) would favorably affect one-year mortality in patients with diabetes.
BACKGROUND Diabetics are known to have increased late mortality following PCI.
METHODS Data from three placebo-controlled trials of PCI, EPIC, EPILOG, and EPISTENT, were
pooled. The one-year mortality rate for patients with a clinical diagnosis of diabetes mellitus
was compared with the rate for nondiabetic patients treated with either abciximab or placebo.
RESULTS In the 1,462 diabetic patients, abciximab decreased the mortality from 4.5% to 2.5%, p 5
0.031, and in the 5,072 nondiabetic patients, from 2.6% to 1.9%, p 5 0.099. In patients with
the clinical syndrome of insulin resistance—defined as diabetes, hypertension, and obesity—
mortality was reduced by abciximab treatment from 5.1% to 2.3%, p 5 0.044. The beneficial
reduction in mortality with abciximab use in diabetics classified as insulin-requiring was from
8.1% to 4.2%, p 5 0.073. Mortality in diabetics who underwent multivessel intervention was
reduced from 7.7% to 0.9% with use of abciximab, p 5 0.018. In a Cox proportional hazards
survival model, the risk ratio for mortality with abciximab use compared with placebo was
0.642 (95% confidence interval 0.458–0.900, p 5 0.010).
CONCLUSIONS Abciximab decreases the mortality of diabetic patients to the level of placebo-treated
nondiabetic patients. This beneficial effect is noteworthy in those diabetic patients who are
also hypertensive and obese and in diabetics undergoing multivessel intervention. Besides its
potential role in reducing repeat intervention for stented diabetic patients, abciximab therapy
should be strongly considered in diabetic patients undergoing PCI to improve their survival.
(J Am Coll Cardiol 2000;35:922–8) © 2000 by the American College of Cardiology
Diabetic patients have higher mortality after both percuta-
neous and surgical coronary revascularization than do pa-
tients without diabetes (1–8). Even in the era of stenting,
diabetics have worse outcomes than do nondiabetics (9–11).
No pharmacological adjunct has yet been demonstrated to
impact upon this increased mortality after coronary inter-
vention. Although mortality from heart disease has been
declining for the general population in the United States,
this is not as true for diabetics (12). Furthermore, the
problem of treating coronary artery disease in diabetics is
likely to increase in the future as this group of patients
increases in size (13,14).
Altered platelet function in diabetics may be one mech-
anism increasing the propensity toward adverse events (15).
Platelet aggregation and adhesion are increased in response
to shear stress in the diabetic patient (16). A diabetic
thrombocytopathy involving platelet hyper-reactivity has
also been described (17). Potentially, even the pre-diabetic
state leads to heightened platelet activity (18). In addition,
the response to arterial injury is different in the presence of
diabetes (19). Microvascular function and coronary flow
reserve are compromised by the diabetic state (20,21).
Furthermore, the entire coagulation cascade appears to be
shifted toward a prothrombotic state (22).
Potent platelet inhibition by glycoprotein IIb/IIIa (GP
IIb/IIIa) inhibitors has been demonstrated to improve
outcomes after percutaneous coronary intervention (PCI)
(23–30). There is evidence to suggest that GP IIb/IIIa
receptor blockade has an even greater effect in diabetic
patients with respect to less need for repeat intervention
among stented patients (31,32). However, no previous trial
has been large enough to assess meaningfully the effect of
abciximab on survival in diabetics. Therefore, we sought to
determine whether the use of GP IIb/IIIa inhibitors at the
time of PCI would reduce the mortality of patients with
diabetes. To do so, we pooled the results of three large-scale
trials of the monoclonal antibody fragment abciximab
(ReoPro™, c7E3Fab, Centocor, Malvern, Pennsylvania)
during coronary intervention: Evaluation of 7E3 for the
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Prevention of Ischemic Complications (EPIC) (33); Eval-
uation in PTCA to Improve Long-term Outcome with
abciximab GP IIb/IIIa blockade (EPILOG) (25); and
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
(EPISTENT) (34).
METHODS
Patient population. Details of the three individual trials
have been provided elsewhere. Informed consent was ob-
tained for all patients enrolled. In brief, the EPIC trial
consisted of 2,099 patients undergoing high-risk angio-
plasty in the setting of severe unstable angina, evolving acute
myocardial infarction (MI), or high-risk coronary morpho-
logical characteristics (33). Patients were randomized to
receive a bolus of abciximab, bolus and infusion of abcix-
imab, or placebo. The EPILOG trial consisted of 2,792
patients undergoing either elective or urgent coronary in-
tervention (25). Patients were randomized to placebo, ab-
ciximab plus standard-dose, weight-adjusted heparin, or
abciximab plus low-dose, weight-adjusted heparin. The
EPISTENT trial included 2,399 patients suitable for either
balloon angioplasty or stenting for elective or urgent indi-
cations (34). Patients were randomized to receive stenting
plus placebo, stenting plus abciximab, or balloon angioplasty
plus abciximab.
Dosing of abciximab. The dose of abciximab used in the
EPIC trial was a 0.25 mg/kg bolus given 10 to 30 min
before the procedure and a 10 mg/min infusion continued
for 12 h after the procedure. Both the EPILOG and
EPISTENT studies used a 0.25 mg/kg bolus 10 to 60 min
before the start of the procedure, followed by a
0.125 mg/kg/min infusion (to a maximum dose of 10
mg/min) for 12 h postprocedure.
Study design. Placebo groups and abciximab bolus and
infusion groups of the three different trials were pooled.
Patients in the arm of the EPIC trial who received the
abciximab bolus only, a regimen not found to be clinically
effective in reducing ischemic complications, were excluded
from the analysis. The classification of patients as diabetic
varied among the three trials’ case report forms. In the
EPIC trial, patients were classified as diabetic if they had a
history of diabetes. They were further classified as insulin-
requiring if insulin was listed among their medications. In
the EPILOG trial, patients were classified by history of
either non-insulin-dependent diabetes or insulin-dependent
diabetes. In the EPISTENT trial, patients were classified as
diabetic based on history. If they were on an oral hypogly-
cemic or insulin therapy at the time of hospital admission,
this was also recorded. Elevated body mass index (BMI) was
defined as greater than 27 kg/m2 in women and greater than
28 kg/m2 in men (35). Patients were categorized as having
the clinical syndrome of insulin resistance if they were
diabetic, hypertensive, and obese (elevated BMI) (36).
All trials defined MI similarly, except for minor variations
to account for enrollment of patients with ongoing MI.
Either new significant Q-waves in two contiguous leads or
elevation of creatine kinase, MB fraction (CK-MB) or CK
greater than three times the upper limit of normal consti-
tuted an MI. The EPIC trial required only one abnormal
enzyme value, whereas the other two trials required two
values. After hospital discharge, MI was defined as either
new Q-waves or elevation of CK-MB or CK greater than
twice the upper limit of normal. When available, CK-MB
took precedence over CK.
Statistical analysis. Data from the three trials were pooled,
and a Breslow-Day test was performed to ensure homoge-
neity of the outcome across trials. Kaplan-Meier survival
estimates and hazard ratios with 95% confidence intervals
(CIs) were calculated for the primary end point of death at
one year. Secondary end points included MI and target
vessel revascularization (TVR). Predetermined subgroups
for analysis were diabetics classified as insulin-requiring,
patients with insulin-resistance syndrome, and diabetics
who underwent multivessel intervention. The log-rank test
was used to compare event rates among treatment groups
for all subgroups. A Cox proportional hazards survival
model was used to calculate hazard ratios and 95% CIs for
the subgroups after adjusting for baseline characteristics in a
final model. An unadjusted alpha value of 0.05 was used for
all analyses. All statistical calculations were performed using
SAS Software, version 6.12 (SAS Institute, Cary, North
Carolina).
RESULTS
Patient characteristics. The baseline characteristics of the
5,072 nondiabetic and the 1,462 diabetic patients are listed
in Table 1. Diabetic patients were more likely to be older,
women, non-Caucasian, or have a history of hypertension,
congestive heart failure (CHF), elevated BMI, or prior
revascularization. Diabetics were less likely to have a prior or
recent (within the last seven days) MI or to smoke currently.
Abbreviations and Acronyms
BMI 5 body mass index
CHF 5 congestive heart failure
CI 5 confidence interval
CK 5 creatine kinase
EPIC 5 Evaluation of 7E3 for the Prevention of
Ischemic Complications
EPILOG 5 Evaluation in PTCA to Improve Long-
term Outcome with abciximab
Glycoprotein IIb/IIIa blockade
EPISTENT 5 Evaluation of Platelet IIb/IIIa Inhibitor
for Stenting
GP IIb/IIIa 5 glycoprotein IIb/IIIa
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
TVR 5 target vessel revascularization
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There were no significant differences between the patients
randomized to placebo or to abciximab.
Mortality. Diabetic patients had a higher one-year mortal-
ity than did nondiabetic patients, 3.3% versus 2.1%, p 5
0.012 (Fig. 1). In the overall cohort, the 4,110 patients
randomized to abciximab had lower mortality than did the
2,424 patients randomized to placebo, 2.0% versus 3.1%,
p 5 0.010 (Fig. 2). Abciximab treatment was associated
with lower mortality in both the diabetic and the nondia-
betic patients (Fig. 3). In nondiabetic patients, those who
received placebo had a 48/1,850 (2.6%) mortality rate
compared with a 61/3,222 (1.9%) rate with abciximab
treatment, p 5 0.099. In diabetic patients, placebo treat-
ment resulted in a 26/574 (4.5%) mortality, versus 22/888
(2.5%) mortality with abciximab, p 5 0.031. The event rate
for diabetics treated with abciximab is comparable to that of
placebo-treated nondiabetic patients. The reduction in mor-
tality in diabetics was seen in both the 931 men (4.9% to
2.7%, p 5 0.083) and the 531 women (4.0% to 2.0%, p 5
0.170).
A mortality reduction in insulin-requiring diabetics with
abciximab treatment was also noted. The one-year mortality
rate for insulin-requiring diabetics treated with placebo was
16/197 (8.1%) versus 11/265 (4.2%) with abciximab treat-
ment, p 5 0.073. In the diabetic patients not receiving
insulin therapy, the mortality rate was reduced from 10/377
(2.7%) to 11/623 (1.8%), p 5 0.341.
Diabetic patients had a reduction in mortality regardless
of whether they had balloon angioplasty or stent implanta-
tion; a Breslow-Day test showed no heterogeneity between
devices, p 5 0.694. Table 2 depicts the mortality rates seen
in the patients who received stents and were randomized to
abciximab. Among patients who underwent multivessel
intervention, the mortality rate was 5/65 (7.7%) for diabetics
receiving placebo versus 1/108 (0.9%) for diabetics receiving
abciximab, p 5 0.018.
Death, MI or TVR. Abciximab also reduced the combined
end point of one-year death, MI, or TVR in diabetic
patients, from 34.3% to 29.1%, p 5 0.022. The rate of MI
was reduced from 11.6% to 6.0%, p , 0.001. This was
principally due to a reduction in the rate of non-Q-wave
MI, which was reduced by abciximab therapy from 9.7% to
4.0%, p , 0.001; the rate of Q-wave MI was 2.2% in both
the placebo and abciximab-treated diabetics. The rate of
TVR was also slightly lower in the patients randomized to
abciximab, 24.2% versus 25.2%, but this was not statistically
significant (p 5 0.674). Of diabetic patients who were
stented, there was less one-year TVR in those receiving
abciximab compared with placebo, 16.7% versus 20.7%,
though this did not reach statistical significance (p 5
0.273). Of diabetic patients who died by one year, 18.7%
had a periprocedural CK elevation greater than three times
the upper limit of normal, versus 8.2% of the diabetic
patients who were alive (p 5 0.010).
Patients with insulin resistance. Patients who were clas-
sified as insulin resistant (i.e., diabetic, hypertensive and
elevated BMI) were at particularly high risk of adverse
events and derived a substantial benefit from abciximab. In
these 720 patients, mortality was reduced by abciximab
Figure 1. The Kaplan-Meier curves for one-year mortality in
diabetics versus nondiabetics.
Figure 2. The Kaplan-Meier curves are shown for one-year
mortality in patients randomized to either placebo or abciximab.
Table 1. Baseline Characteristics of Patients Classified as
Diabetic or Nondiabetic
Nondiabetic
(n 5 5,072)
Diabetic
(n 5 1,462) p Value
Age (yrs) 59.4 60.9 , 0.001
Women 24.0% 36.3% , 0.001
Non-Caucasian 8.1% 15.0% , 0.001
Hypertension 51.5% 70.9% , 0.001
CHF 4.8% 12.3% , 0.001
Prior CABG 10.6% 15.9% , 0.001
Prior PTCA 20.2% 23.9% 0.003
Prior MI 51.4% 48.8% 0.081
Recent MI 20.7% 15.7% , 0.001
BMI (mean) 28.2 30.6 , 0.001
Current smoking 37.0 25.6 , 0.001
Extent of disease 0.513
1-vessel 67.9 67.0
2-vessel 22.1 22.0
3-vessel 8.1 9.3
BMI 5 body mass index in kg/m2; CABG 5 coronary artery bypass grafting; CHF 5
congestive heart failure; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty.
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treatment from 5.1% to 2.3%, p 5 0.044, MI was reduced
from 12.0% to 7.1%, p 5 0.024, and TVR was reduced from
32.7% to 25.7%, p 5 0.048. The combined end point of
death, MI or TVR was reduced from 42.6% to 31.3%, p 5
0.002.
Bleeding. Slightly more bleeding occurred in diabetic pa-
tients treated with abciximab versus placebo; however, the
differences in the rates of major bleeding (4.3% vs. 3.0%,
p 5 0.21) or of minor bleeding (6.9% vs. 6.3%, p 5 0.66)
were not statistically significant. The incidence of intracra-
nial hemorrhage was very low in diabetic patients receiving
placebo or abciximab (0.17% vs. 0%, p 5 0.39).
Consistency of benefit in each trial. The benefit of
abciximab in diabetics was seen in each of the three trials
that were pooled; a Breslow-Day test showed no heteroge-
neity among the three trials that were combined for this
analysis, p 5 0.745. In the EPIC trial the risk ratio for
one-year mortality in diabetics treated with abciximab
compared with placebo was 0.995 (95% CI 0.384–2.579); in
EPILOG, the risk ratio was 0.430 (95% CI 0.170–1.089);
and in EPISTENT, the risk ratio was 0.457 (95% CI
0.154–1.361). The pooled data showed a risk ratio of 0.541
(95% CI 0.306–0.954), p 5 0.034 (Fig. 4).
Multivariable modeling. Multivariable modeling for pre-
dictors of one-year mortality in the overall cohort revealed
that abciximab use at the time of intervention was protec-
tive, with a hazard ratio of 0.642, p 5 0.010 (Table 3). The
other predictors of mortality were a history of insulin-
requiring diabetes, hypertension, CHF, age greater than or
equal to 65 years, or a Type B2/C lesion. Stenting appeared
to confer a protective effect. Other factors that were entered
into the model but were not significant included gender,
race, BMI, smoking status, multivessel disease, and history
of MI. Restricting the analysis to diabetic patients, those
categorized as insulin-requiring had a hazard ratio for
mortality of 2.22 (95% CI 1.214–4.058), p 5 0.010, after
adjusting for the same significant predictors listed above.
DISCUSSION
Diabetic patients have worse outcomes after PCI than do
nondiabetic patients. Abciximab has been shown to improve
outcomes after PCI in a broad range of patients (34). In
addition to its beneficial effects on reducing periprocedural
MI and the need for urgent revascularization, abciximab has
more recently been shown to decrease mortality after stent-
ing (37). The purpose of this investigation was to determine
whether there is a mortality benefit of abciximab use in
diabetic patients, given their high-risk profile. We found a
striking 44% reduction in one-year mortality among dia-
betic patients who were randomized to treatment with
abciximab at the time of PCI. Treatment with abciximab
essentially equalized outcomes of diabetic patients to those
of placebo-treated nondiabetics. The benefit of abciximab in
diabetic patients was evident in the combined end point of
death, MI or TVR as well.
The patients classified as insulin-requiring had an even
higher mortality than did the non-insulin-requiring diabetic
patients, as previous studies have also reported (38). In our
analysis abciximab appeared to have a strong mortality
benefit in those patients receiving insulin. It is impossible to
determine from this study whether insulin treatment merely
served as a marker for more severe diabetes or whether
insulin therapy itself had a deleterious effect. Diabetic
patients who were also hypertensive and obese (elevated
BMI) had particularly high rates of adverse outcomes.
Abciximab reduced the one-year risk of death, MI or TVR
by over 25% in this high-risk cohort.
Whether stenting per se improves outcomes in diabetics
has been debated. While it appears that stenting may reduce
the restenosis rate in diabetics, it does not impact on their
higher risk of MI or death (39,40). In our study, the
combination of abciximab and stent placement produced
particularly favorable results in diabetics. Thus, the combi-
Figure 3. The Kaplan-Meier curves are shown for one-year
mortality in diabetics and nondiabetics randomized to either
placebo (PL) or abciximab (ABX).
Table 2. One-Year Mortality Rates in Patients Undergoing Either Balloon Angioplasty or Stent
Placement Who Were Randomized to Placebo or Abciximab
Placebo
(n 5 2,252)
Abciximab
(n 5 3,844)
p
Value
Nondiabetic/Balloon 30/995 (3.0%) 44/2082 (2.1%) 0.127
Diabetic/Balloon 17/343 (5.0%) 18/614 (2.9%) 0.110
Nondiabetic/Stent 13/717 (1.8%) 11/918 (1.2%) 0.305
Diabetic/Stent 9/197 (4.6%) 3/230 (1.3%) 0.042
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nation of abciximab with stenting may be the optimal
percutaneous revascularization strategy, not only for reduc-
ing TVR (32) but also for improving survival.
Previous studies have suggested that diabetic patients
who undergo multivessel angioplasty have increased mor-
tality compared to those who undergo bypass surgery
(41–45). These studies have prompted consideration of
abandoning multivessel intervention in the diabetic popu-
lation (46). Our analysis showed a reduction in mortality
among diabetics randomized to abciximab who had mul-
tivessel intervention performed. Given the remarkable ben-
efit of abciximab in reducing mortality in diabetics, the issue
of multivessel PCI with concomitant GP IIb/IIIa inhibition
(and stents) versus coronary artery bypass surgery with
arterial grafts should be reexplored (47–49).
Potential mechanism of benefit. The mechanism of ab-
ciximab’s marked benefit in reducing mortality in diabetics
is unclear. A larger proportion of the patients who died had
a significant periprocedural elevation in cardiac enzyme
levels than did patients who did not die. Abciximab has a
powerful ability to reduce periprocedural MI, and part of its
effect on mortality may be mediated through this effect.
However, the majority of patients who died did not have a
periprocedural MI. Thus, other protective mechanisms of
abciximab must be operative.
Prevention of distal embolization and microvascular in-
jury may be of long-term importance. The microvasculature
of diabetics is often diffusely diseased and may be poorly
suited to handle the thromboembolic burden created by
PCI. Perhaps instrumentation of the artery and microscopic
injury contribute to new lesion development (50). Peripro-
cedural abciximab administration may attenuate the re-
sponse of the endothelium to such injury by means of its
binding to receptors other than the GP IIb/IIIa receptor
(51). Abciximab’s modulation of cell adhesion molecules
may be of particular importance in the diabetic (52,53).
Abciximab’s possible benefit in reducing neointimal growth,
as documented by angiography in stented patients, is an-
other intriguing mechanism of benefit (31,32,54). The
success of the one-time administration of an antiplatelet
agent at the time of intervention raises the possibility of
even greater improvement in outcomes with long-term oral
antiplatelet therapy (55).
Study limitations. There were certain limitations to this
study. This was not a dedicated, randomized clinical trial of
diabetic patients, but rather a retrospective analysis of the
cohort of diabetics from the three trials studied. However,
the assignment to abciximab was randomized, and the
placebo and drug groups appeared well balanced. Detailed
information about diabetic status was not collected. There
was no information about fasting glucose values or levels of
glycosylated hemoglobin. Thus, the severity and extent of
control of diabetes was not known, nor was the duration.
Furthermore, classification of diabetics as insulin-
requiring or non-insulin-requiring was based on whether
patients were taking insulin. Information about specific
medications used to treat diabetes was incomplete; sulfonyl-
ureas may themselves increase mortality in diabetics in
certain settings (56–58). Differentiation between diabetics
taking oral medication or diabetics treated with dietary
modification alone was not possible. Data on hyperlipid-
emia were also incomplete. In addition, in the patients who
died, the actual cause of death was not recorded.
Conclusions. Diabetic patients, and insulin-requiring dia-
betics in particular, derived a significant one-year mortality
benefit from prophylactic abciximab administration at the
time of either balloon angioplasty or stent deployment.
Further investigation is necessary to delineate the precise
mechanism responsible for this reduction in mortality.
Abciximab use should be strongly considered at the time of
intervention in diabetic patients, especially those who are
being treated with insulin or are also hypertensive and
obese.
Finally, based on our findings, a randomized trial of PCI
with concomitant GP IIb/IIIa blockade versus coronary
artery bypass surgery may be warranted to establish the
superior mode of revascularization in diabetics with mul-
tivessel coronary disease.
Figure 4. Hazard ratios are shown for abciximab versus placebo in
diabetic patients for each of the three trials analyzed.
Table 3. Cox Proportional Hazards Survival Model for
One-Year Mortality in All Patients From the EPIC,
EPILOG and EPISTENT Trials
Variable
Hazard Ratio
(95% CI) p Value
Abciximab vs. placebo 0.642 (0.458, 0.900) 0.010
Diabetes 1.222 (0.845, 1.767) 0.287
Stent vs. balloon only 0.702 (0.474, 1.039) 0.077
Previous intervention 0.554 (0.341, 0.901) 0.017
Age $65 years 1.776 (1.260, 2.503) 0.001
Hypertension 1.657 (1.138, 2.413) 0.008
CHF 3.591 (2.398, 5.378) , 0.001
Type B2/C lesion 1.734 (1.096, 2.742) 0.019
CHF 5 congestive heart failure; Type B2/C lesion refers to modified ACC lesion
criteria.
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